Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

Pediatric cystic fibrosis patients treated using Vertex Pharmaceuticals’ oral CFTR potentiator VX-770 demonstrated significant improvements in lung function after 24 weeks of treatment ...

Ono will assist with Vertex's clinical trials for povetacicept and handle marketing approvals in Japan and South Korea, focusing on IgAN and pMN with possible additional uses.

Researchers reported that the small, 20-patient study revealed improved lung function in patients taking the oral drug. There was no discerned improvement in patients taking a placebo.

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment and now is expanding into other areas that could bring in billion-dollar revenue.

Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Vertex Pharmaceuticals VRTX initiated the late-stage portion of the phase II/III AMPLITUDE study evaluating inaxaplin (VX-147) in APOL1-mediated kidney disease (AMKD), a genetic disorder affecting ...

May 1 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O on Thursday said a combination of its cystic fibrosis drug Kalydeco with an experimental compound was shown to improve lung function in a mid-stage ...